Akeso, Inc. announced that Ligufalimab and Ivonescimab have obtained approval from the Center for Drug Evaluation of the National Medical Products Administration of the People’s Republic of China to initiate a Phase II clinical trial with chemotherapy as first-line therapy for unresectable locally advanced or metastatic triple negative breast cancer.
[Akeso, Inc. (PR Newswire, Inc.)]
7992332
{7992332:BBBBBBBB}
apa
50
1
171383
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
